Bio-Rad Laboratories, Inc.

Total Valuation

Bio-Rad Laboratories, Inc. carries a market capitalization of 8.24B, placing it among publicly traded companies globally. Its enterprise value stands at 7.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Bio-Rad Laboratories, Inc. currently has 26.83M shares outstanding.

Valuation Ratios

Bio-Rad Laboratories, Inc. trades at a trailing price-to-earnings ratio of 44.59. The price-to-sales ratio is 2.91, and the price-to-book ratio stands at 0.98.

Enterprise Valuation

On an enterprise value basis, Bio-Rad Laboratories, Inc. trades at an EV/EBITDA multiple of 18.48 and an EV/FCF ratio of 10.47. The EV/Sales ratio of 2.83 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 32.06 provides insight into valuation relative to core operating earnings.

Financial Position

Bio-Rad Laboratories, Inc. maintains a current ratio of 3.21, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.12, indicating elevated leverage, while an interest coverage ratio of 8.06 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Bio-Rad Laboratories, Inc. posts a return on equity of 2.23 and a return on invested capital of 2.13.

Taxes

Over the trailing twelve months, Bio-Rad Laboratories, Inc. has paid 53.50M in income taxes, reflecting an effective tax rate of 24.07.

Stock Price Statistics

Bio-Rad Laboratories, Inc.'s stock has gained approximately 21.90099% over the past 52 weeks. The 50-day moving average sits at 275.47, while the 200-day moving average is 285.15.

Income Statement

Over the trailing twelve months, Bio-Rad Laboratories, Inc. generated 2.59B in revenue and converted that into 168.80M in net income, yielding earnings per share of 6.24. EBITDA reached 397.20M, while operating income came in at 229.00M.

Balance Sheet

Bio-Rad Laboratories, Inc. holds 1.56B in cash and equivalents against 1.38B in total debt, resulting in a net debt position of 696.20M. Total book value stands at 7.65B, with working capital of 2.03B providing operational flexibility.

Cash Flow

Bio-Rad Laboratories, Inc. produced 510.40M in operating cash flow over the past twelve months. After subtracting -153.20M in capital expenditures, free cash flow totaled 357.20M - equivalent to 13.20 per share.

Margins

Bio-Rad Laboratories, Inc. operates with a gross margin of 51.87, reflecting its pricing power and cost economics. The operating margin of 8.84 and net profit margin of 6.52 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Bio-Rad Laboratories, Inc.'s most recent stock split took place on March 8, 2002 with a 1:2 split ratio.

Scores

Bio-Rad Laboratories, Inc. posts an Altman Z-Score of 3.36, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.